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Invasive external otitis begins in the external auditory canal and extends to involve the adjacent subcutaneous tissues and temporal bone. The clinical course consists of a chronic osteomyelitis of the base of the skull that is usually slowly progressive and may be associated with cranial nerve involvement. Prompt diagnosis and prolonged therapy with intravenous antibiotics active against Pseudomonas are essential to the reduction of morbidity and mortality. Results of therapy are best in patients without evidence of neurologic involvement at the time of initial diagnosis [1] .
Organisms other than Pseudomonas aeruginosa that have been recovered from the external auditory canal or surgical specimens in invasive external otitis include Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus species, Candida parapsilosis, Candida albicans, the enterococcus, Streptococcus species, and diphtheroid species [1] . The significance of these organisms in this setting is uncertain. A review of invasive external otitis indicated that P aeruginosa accounted for 99.2% of 262 reported cases [2] . We report a case of invasive external otitis caused by Aspergillus and treated successfully with itraconazole. A literature review identified four other cases of invasive aspergillus otitis.
Case Report
A 64-year-old woman was admitted to the hospital Reports of the definite cases are summarized in table 1. None of the previously reported cases were in diabetic patients. All but one patient had hematologic malignancy, including preleukemia and acute leukemia. Cranial neuropathy involving the facial nerve was common to all confirmed cases, with one instance of multiple cranial nerve involvement. Three patients were treated with a combination of systemic antifungal therapy and surgical debridement. The total dose of amphotericin B ranged from 1,500 to 2,500 mg. However, relapses were noted after courses of 1,500 and 2,000 mg of amphotericin B in cases no. 2 and 4, respectively; both of these patients had also been treated surgically. Favorable outcomes were associated with additional courses of antifungal therapy as outlined in table 1. Surgical therapy consisted of mastoidectomy, temporal bone debridement, or debridement of the pinna. None of the patients with definite cases died as a result of invasive otitis.
The case we considered to be probable was included in a review of invasive aspergillosis primarily involving patients with hematologic malignancy or solid tumors [10] . Culture of the exudate from the external ear yielded Aspergillus species and Serratia marcescens. Treatment was initiated with amphotericin B; the patient died 12 days later, after receiving a total dose of 531 mg. Autopsy revealed invasive pulmonary aspergillosis; however, the histopathologic findings for the ears and adjacent tissues were not described.
Itraconazole is a triazole antifungal agent. Its spectrum of activity, including Aspergillusfumigatus, and its lack of documented hepatic or endocrinologic toxicity distinguish it from ketoconazole [11, 12] . Itraconazole is available only as an oral formulation, and its absorption has been poor in some patients, particularly those with leukemia who are undergoing cytotoxic chemotherapy [13] . Uncertainty regarding oral absorption and fungistatic (rather than fungicidal) activity has made some in- vestigators reluctant to study ketoconazole and itraconazole in the mangement of deep fungal infections in severely immunocompromised patients. Although it is difficult to draw conclusions from the limited published experience with itraconazole for invasive aspergillus infections [14] [15] [16] [17] , preliminary observations have been encouraging. In our patient, who was intolerant of amphotericin B, it was hoped that itraconazole would suppress the infection. There were no signs of persistent otic infection in the 3-month period following itraconazole therapy and prior to the patient's death, which was caused by leukemic relapse. A distinction between suppression and cure of infection could not be made.
This case illustrates two points. First, organisms other than R aeruginosa may be responsible for invasive otitis externa in the immunocompromised host; this point underscores the importance of obtaining an etiologic diagnosis. Second, our experience provides further support for the use of itraconazole as an alternative to amphotericin B in the management of invasive aspergillosis.
